Contraindications of Ruxolitinib
Ruxolitinib (Jakafi) has NO formal contraindications according to the FDA-approved prescribing information 1.
Important Clarification
While there are no absolute contraindications listed in the drug label, there are several critical situations where ruxolitinib should be avoided or used with extreme caution:
Situations Requiring Avoidance or Dose Modification
Pregnancy and Lactation
- Avoid use during pregnancy - animal studies demonstrate teratogenicity, and women of childbearing age must use effective contraception 2, 1
- Avoid during breastfeeding - insufficient human data on lactation safety 2, 1
Severe Organ Dysfunction
- Decompensated advanced chronic liver disease (Child-Pugh score ≥9, presence of ascites, hepatic encephalopathy grade ≥2, or variceal bleeding) - requires dose reduction or avoidance 2
- Severe renal impairment (creatinine clearance <30 mL/min) - requires dose modification; certain formulations are contraindicated with CrCl <15 mL/min 2, 1
Thromboembolic History
- History of arterial or venous thromboembolic events - JAK inhibitors increase thrombosis risk in a dose-dependent manner compared to TNF inhibitors; careful risk-benefit assessment required 2
Active Infections
- Serious active infections must be resolved before initiating therapy - JAK inhibitors increase infection risk, including tuberculosis, opportunistic infections, and herpes zoster 2, 1
Malignancy History
- Current or history of malignancies - particularly concerning in patients with prior malignancies within 5 years, though not an absolute contraindication; increased risk of non-melanoma skin cancer and potential lung cancer risk in high-risk populations 2
Live Vaccines
- Avoid live vaccines during treatment - immunosuppressive effects preclude safe administration 2
Key Clinical Pitfalls
The absence of formal contraindications does not mean ruxolitinib is universally safe. The "boxed warning paradox" exists where topical formulations carry warnings despite lower systemic exposure than oral forms 3. Clinicians must distinguish between:
- Absolute avoidance (pregnancy, active serious infection, decompensated liver disease)
- Dose modification required (moderate-severe renal/hepatic impairment)
- Enhanced monitoring needed (history of thrombosis, prior malignancy)
The FDA label explicitly states "CONTRAINDICATIONS: None" 1, but this should be interpreted within the context of the extensive warnings and precautions that effectively limit use in high-risk populations.